Therefore, presumably the ARGs identified either in our study or elsewhere might hold promise as a novel biomarker for human HCC therapy, making the development and test of the effect of ARG inhibitors clinically desirable. This evidence concerns the gene SERPINA2 and hepatocellular carcinoma.